The Bombay High Court’s decision in Ms. C.B. Healthcare and Ors. v. Union of India is a significant reminder that prosecutions under the Drugs and Cosmetics Act, 1940 must satisfy not only public health objectives but also the statutory safeguards built into the Act and the Rules. In a judgment delivered on 24 March 2026, Justice N.J. Jamadar quashed the criminal prosecution against the manufacturer and its partners, holding that the cumulative procedural lapses had destroyed the accused’s valuable right to challenge the analyst’s report and had rendered the continuation of prosecution an abuse of the process of court.
Facts and procedural history
The petitioners were a pharmaceutical manufacturing firm, C.B. Healthcare, and its partners. The firm had manufactured FEXINOL-12 tablets, and a sample of Batch No. CBT-40016 was drawn on 29 November 2016 by a Drugs Inspector from the Central Medical Store at Silvassa for test and analysis.
One sealed portion of the sample was sent to the Central Drugs Testing Laboratory, Mumbai on 30 November 2016. The Government Analyst issued a report in Form No. 13 in July 2017 declaring the sample to be “not of standard quality.”
The matter was then investigated further, sanction for prosecution was obtained on 6 November 2019, and the complaint came to be filed only on 28 September 2021 before the Special Judge at Silvassa for an offence punishable under Section 27(d) of the Drugs and Cosmetics Act, 1940. The petitioners invoked the writ jurisdiction of the High Court to challenge the prosecution, the order issuing process, and the legality of the proceedings on several grounds rooted in statutory non-compliance and procedural illegality.
Structure of the challenge
The High Court noticed that the petitioners’ objections could broadly be arranged in two clusters. The first cluster concerned violations of the substantive procedural safeguards under the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945, especially delay in testing, non-supply of the sample portion to the manufacturer, and the consequential loss of the right to reanalysis.
The second cluster related to defects in the prosecution itself after sanction, namely direct cognizance by the Special Judge without committal, mechanical issuance of process, and absence of specific averments to fasten vicarious liability on the partner-accused. The Court chose to first examine the statutory violations relating to sampling and testing, treating them as the foundation of the challenge.
Rule 45 and delayed analysis
A substantial part of the judgment is devoted to Rule 45 of the Drugs Rules, 1945. The Rule requires the Government Analyst to test or analyse the sample and furnish the report within 60 days of receipt, and where that is not possible, the Government Analyst must seek extension of time from the Government by giving specific reasons.
In the present case, the sample was sent on 30 November 2016, but the analyst’s report was issued only in July 2017. The Court held that this was a clear breach of the timeline prescribed by Rule 45, and the breach could not be cured by an ex post facto explanation in the affidavit of the prosecuting authority that reference and impurity standards were not readily available.
Justice Jamadar emphasized that the Rule is couched in mandatory language. The use of the word “shall” both in the main part of Rule 45 and in its proviso showed that timely testing is not a matter of convenience but a legal obligation, and if delay becomes unavoidable, the statute itself prescribes the only lawful method to deal with it, namely, a formal request for extension by the Government Analyst.
The Court also explained the rationale behind the time limit. Delay in testing can affect the physical and chemical properties of the drug, undermine the reliability of the analytical report, and compromise the fairness of the prosecution, particularly where the accused has a statutory right to seek reanalysis.
In this sense, Rule 45 was treated not merely as an administrative direction but as a procedural safeguard intimately linked to the defence rights of the accused. The Court therefore held that the delayed testing had materially dented the prosecution.
Section 23 and failure to supply sample
The second major infirmity arose from non-compliance with Section 23 of the Act. Under Section 23(3) and Section 23(4), where a sample is taken for test or analysis, the Inspector must divide it into the requisite portions, return one portion to the person from whom it is taken, send one to the Government Analyst, produce one before the court, and send the remaining portion to the person whose name and particulars are disclosed under Section 18A.
In the present case, the Court found that one portion of the sample was not sent to the manufacturer, C.B. Healthcare, even though the material on record clearly disclosed that the authorities knew who the manufacturer was. The Section 18A notice was sent to the distributor, and although a copy of the notice was marked to the manufacturer, the manufacturer did not receive the sample portion itself.
This omission was not inconsequential. The manufacturer specifically requested that a sample portion be forwarded to it, but the request was not accepted. The Court therefore concluded that the statutory mechanism intended to preserve the manufacturer’s opportunity to challenge the report had not been properly observed.
Section 25 and the lost right of reanalysis
The judgment then proceeds to the heart of the matter: the valuable right under Section 25 of the Act. Section 25 gives evidentiary value to the Government Analyst’s report, but it also permits the accused, subject to statutory conditions, to controvert that report and seek reanalysis by the Central Drugs Laboratory through the court.
The respondent argued that the petitioners had failed to notify their intention to adduce evidence in controversion of the analyst’s report within the period prescribed by Section 25(3), and therefore could not later complain of prejudice. The High Court accepted the legal principle that Section 25(3) is important, but held that the argument could not be mechanically applied in the facts of the present case because the manufacturer had not been sent the sample portion and the complaint itself was filed long after the shelf life of the drug had expired.
The Court noted that the drug had been manufactured in September 2016 and had expired in August 2018, whereas the complaint was filed only on 28 September 2021. By then, more than three years had passed after expiry, and the sample had plainly lost shelf life.
This meant that even if the petitioners had sought an order from the court under Section 25(4), the sample could not have been meaningfully sent for reanalysis by the Central Drugs Laboratory. The accused’s statutory right had, in practical terms, been extinguished by the prosecution’s own delay and inaction.
That conclusion is central to the judgment. The Court did not treat the prejudice as speculative; it held that the right to retesting had been concretely defeated by a series of prosecutorial defaults.
Reliance on Supreme Court precedent
The judgment is doctrinally strong because it is anchored in Supreme Court authority. The High Court referred to State of Haryana v. Brij Lal Mittal for the proposition that the right under Section 25(4) ordinarily depends upon compliance with Section 25(3), but it also took note of subsequent authority that prevents the prosecution from taking advantage of its own default.
The Court relied on Amery Pharmaceuticals v. State of Rajasthan to examine the statutory scheme regarding supply of sample portions and the rights of persons in the distribution chain. It then drew support from Laborate Pharmaceuticals India Ltd. v. State of Tamil Nadu, where the Supreme Court quashed prosecution on the ground that the manufacturer’s valuable right of reanalysis had been denied by failure to send part of the sample and by delay in taking cognizance.
Equally important was the Court’s reliance on Medipol Pharmaceutical India Pvt. Ltd. v. PGIMER, in which the Supreme Court reiterated that where delay attributable to the State destroys the utility of the sample and the right to appellate analysis, prosecution or penalty based on such testing cannot be sustained. Justice Jamadar applied these principles to hold that the present case had become, in substance, a lame prosecution.
Direct cognizance by the Special Court
Although the Court had already found the prosecution unsustainable on the preceding grounds, it still dealt with an additional and significant procedural issue: whether the Special Judge could directly take cognizance of the offence under Section 27(d). The Court answered this in the negative.
Section 32(2) of the Drugs and Cosmetics Act states that no court inferior to a Court of Session shall try an offence punishable under Chapter IV. However, the High Court pointed out that this provision identifies the forum of trial; it does not, by itself, authorize the Court of Session to take cognizance as a court of original jurisdiction without committal.
That distinction was crucial because Section 193 of the Code of Criminal Procedure bars a Court of Session from taking cognizance directly unless the case has been committed to it by a Magistrate, except where the Code or another law expressly provides otherwise. The Drugs and Cosmetics Act contains no express provision authorizing direct cognizance by the Sessions Court for an offence under Section 27(d).
The High Court therefore held that the ordinary CrPC route continued to apply. In other words, the complaint ought to have first been presented before the Magistrate, and only after committal could the Sessions Court have proceeded further.
Why the Special Court notification did not help
The prosecution attempted to rely on a notification of the Union Territory designating the Principal District Judge at Silvassa as a Special Court. The argument was that, once a Special Court had been designated, the bar in Section 193 CrPC stood neutralized.
The Court rejected that submission. It held that a notification designating a forum for trial is not equivalent to a statutory provision conferring power of direct cognizance.
Justice Jamadar further observed that the notification had been issued under Section 36AB(1), which concerns Special Courts for specified offences relating to adulterated or spurious drugs and other enumerated categories. The case before the Court, however, involved an offence under Section 27(d), and in any event the notification could not create a power of direct cognizance where the parent statute itself did not expressly confer one.
This aspect of the judgment is important for criminal procedure. It reiterates that the designation of a Special Court may affect the forum of trial, but it does not automatically alter the statutory route by which that court acquires jurisdiction.
Role of Union of India v. Ashok Kumar Sharma
To reinforce its conclusion on cognizance, the High Court relied on the Supreme Court’s decision in Union of India v. Ashok Kumar Sharma. The Supreme Court had clarified that Section 32 is indeed a special provision identifying who can set the criminal process in motion, but it does not displace the complaint procedure under the CrPC unless the statute expressly says so.
The significance of Ashok Kumar Sharma lies in its insistence that one must distinguish between the right to institute a complaint and the procedural path by which the competent court takes cognizance. Even where the Drugs Act restricts locus to specified persons, the CrPC continues to govern the mechanics of cognizance unless specifically excluded.
Applied to the present case, that meant that the Special Judge could not assume original cognizance merely because he was the designated trial forum. The procedural gateway under Section 193 CrPC remained intact.
Vicarious liability of partners
The Court also touched upon the allegations against the partner-accused. It found that the complaint did not contain sufficient particulars explaining how each partner was in charge of and responsible for the conduct of the business at the relevant time.
The Court reiterated the established principle that vicarious liability under Section 34 of the Drugs and Cosmetics Act cannot be imposed by merely reproducing the statutory formula or by making bald assertions. The complaint must disclose the role of each accused with adequate factual specificity.
Though this was not the primary basis of the final decision, it reinforces an important prosecutorial discipline. In regulatory offences carrying penal consequences, form allegations against directors, partners, or office-bearers are not enough.
The larger significance of the ruling
This judgment deserves close reading because it unites three important ideas. First, compliance with timelines and sampling safeguards under the Drugs Rules and the Act is not a matter of procedural ornamentation but of substantive fairness.
Second, the accused’s right to challenge the Government Analyst’s report is a real and valuable right, and if that right is frustrated by delay attributable to the prosecution, the prosecution itself may collapse. Third, special statutory forums do not automatically erase foundational criminal procedure requirements unless the statute expressly says so.
For judges, the ruling offers a careful reconciliation of public interest in drug regulation with the procedural discipline demanded by criminal law. For advocates, it is a useful precedent on how chronology, shelf life, statutory notice, and cognizance procedure can become decisive in a prosecution under the Drugs and Cosmetics Act.
Conclusion
The Bombay High Court ultimately held that the prosecution suffered from insurmountable infirmities. The delayed analysis under Rule 45, the failure to send the sample portion to the manufacturer, the destruction of the right to reanalysis under Section 25, the defective route of direct cognizance, and the weak averments regarding vicarious liability together made the continuation of proceedings legally unsustainable.
Accordingly, the Court quashed the order issuing process as well as the criminal case itself. The decision stands as an important reaffirmation that in criminal prosecutions under regulatory statutes, procedural safeguards are not technical obstacles to enforcement; they are conditions of lawful prosecution.
No comments:
Post a Comment